BIOCHECK, INC.

BioCheck, Inc. is a leader in value-based diagnostics and data monetization, offering high-quality in vitro diagnostic immunoassay devices. The company manufactures and distributes a comprehensive range of diagnostic products including instruments, antibodies, and ELISA kits designed for clinical and research applications. Following the August 2021 acquisition of DRG International, BioCheck operates a global network with subsidiaries and offices across the USA, Germany, Russia, Poland, and Czech Republic, providing distribution capacity to customers in over 110 countries. The DRG:HYBRiD-XL® is a fully automated analyzer for immunoassays and clinical chemistry. Product lines span diagnostic ELISAs, chemiluminescent assays, and specialized antibodies for applications including diabetes diagnosis, endocrinology, prenatal/neonatal supervision, and thyroid function testing. BioCheck emphasizes value-based diagnostics—delivering cost-effective, evidence-based diagnostic testing to improve patient outcomes and reduce unnecessary testing—alongside healthcare data monetization and shared savings models. The company aligns with well-established diagnostic principles, focusing on accessible, reliable tools for hospitals, clinics, research laboratories, and resource-limited settings.